Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The TEEL Study: Ribociclib + Tamoxifen in Advanced Breast Cancer
NCT02586675Phase 1Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Feb 2016
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ribociclib in breast cancer, sponsored by Moffitt Cancer Center. Primary endpoint: Recommended Phase II Dose at 12 months. Started Feb 2016; status: completed.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02586675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02586675.